Abstract
INTERLEUKIN-2 (IL-2) is a T-cell derived molecule implicated in the clonal expansion of antigen-activated T cells1 and in T-cell development2. IL-2 is also implicated in autoimmune disease3, although its role is still controversial4,5. Murine systemic lupus erythematosus (SLE) is a good model for human SLE as most of the immunological abnormalities in the human disease also seem to be operative in the mouse6. Among SLE mice, the MRL/lpr strain develops early in life autoimmune diseases such as immune complex-mediated glomerulonephritis, arthritis and arteritis7,8. Lymphoid abnormalities associated with those diseases in this strain are thymic atrophy and abnormal proliferation of CD3+ CD4− CD8− 'double-negative' T cells, resulting in massive generalized lymph node enlargement. We have therefore now examined the effects of IL-2 on the disease progression in MRL/lpr mice9 using live vaccinia recombinant viruses expressing the human IL-2 gene10. Vaccinated mice showed prolonged survival, decreased autoantibody and rheumatoid factor titres, marked attenuation of kidney interstitial infiltration and intraglomerular proliferation, as well as clearance of synovial mononuclear infiltrates. Inoculation with the IL-2/vaccinia recombinant virus led, in addition, to drastic reduction of the double-negative T-cell population, improved thymic differentiation and restoration of normal values of mature cells in peripheral lymphoid organs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Moller, G. (ed.) Immun. Rev. 63, 1–209 (1981).
Toribio, M. L. et al. Nature 342, 82–85 (1989).
Altman, A. et al. J. exp. Med. 154, 791–808 (1981).
Linker-Israeli, M. et al. J. Immun. 130, 2651–2655 (1983).
Weston, K. M. et al. J. Immun. 131, 734–742 (1988).
Theofilopoulos, R. & Dixon, F. J. Adv. Immun. 37, 269–390 (1985).
Katagiri, T., Cohen, P. L. & Eisenberg, R. A. J. exp. Med 167, 741–751 (1988).
Miescher, G. et al. J. Immun. 138, 1959–1967 (1987).
Dixon, F. J. Immun Today 2, 145–147 (1981).
Flexner, C., Hugin, A. & Moss, B. Nature 330, 259–261 (1987).
Katagir, T. et al. J. exp. Med. 167, 741–751 (1988).
Mountz, J. et al. J. Immun. 140, 2943–2949 (1988).
Cohen, P. L., Rapoport, J. & Eisenberg, R. A. Clin. Immun. Immunopath. 40, 485–491 (1986).
Budd, R. C. et al. J. Immun 135, 3704–3711 (1985).
Ramshaw, I. A. et al. Nature 329, 545–546 (1987).
Wadsworth, S., Yui, K. & Greene, M. I. Proc. natn. Acad. Sci. U.S.A. 86, 1018–1022 (1988).
Sakaguchi, S. et al. J. exp. Med. 161, 72–87 (1985).
Singer, P. A. et al. Proc. natn. Acad. Sci. U.S.A. 83, 7018–7022 (1986).
Nemazee, D. A. et al. Eur. J. Immun. 15, 760–764 (1988).
Marcos, M. A. R. et al. Scand. J. Immun. 25, 321–333 (1987).
Clark, F. et al. Proc. natn. Acad. Sci. U.S.A. 81, 2543–2547 (1984).
Chakrabarti, S., Brechling, R. & Moss, B. Molec. cell. Biol. 5, 3403–3409 (1985).
Leo, O. et al. Proc. natn. Acad. Sci. U.S.A. 84, 1374–1391 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gutierrez-Ramos, J., Andreu, J., Revilla, Y. et al. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 346, 271–274 (1990). https://doi.org/10.1038/346271a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/346271a0
This article is cited by
-
Regulatory T cells in the treatment of disease
Nature Reviews Drug Discovery (2018)
-
Low-Dose IL-2 in the Treatment of Lupus
Current Rheumatology Reports (2016)
-
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Nature Reviews Immunology (2015)
-
Immunopathology and the gene therapy of lupus
Gene Therapy (2003)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
